Literature DB >> 31490196

"Personalized Excision" of Malignant Melanoma-Need for a Paradigm Shift in the Beginning Era of Personalized Medicine.

Wolfgang Weyers1.   

Abstract

The premises on which guidelines for the excision of primary cutaneous melanoma are based are illogical and fail to take into account peculiarities of the individual lesion. The horizontal margins of excision continue to be adjusted to the vertical thickness of the neoplasm, and recommended clinical margins do not reflect the histopathologic borders of melanoma. Micrographically controlled surgery has become accepted for acral melanomas and melanomas of the face and neck but not for melanomas on the trunk, arms, and legs, although the latter tend to be more sharply confined. Extending margins of excision for the purpose of removing inapparent metastases is fallacious because the latter are rare, their localization cannot be foretold, and satellite metastases are usually associated with distant metastases, so that patients do not profit from early removal of cutaneous lesions. The only meaningful objective of excision is complete removal of the primary melanoma. The success of excision must be controlled histopathologically. Because of limitations of the method, a histopathologic safety margin should be observed that must depend on the characteristics of the individual lesion. In sharply confined melanomas, a histopathologic margin of at least 1 mm is sufficient. In the case of poor demarcation, with solitary atypical melanocytes extending far beyond the bulk of the lesion, a broader histopathologic safety margin is advisable. Special caution should be exercised in the presence of regression and for desmoplastic melanomas, acral melanomas, and melanomas on the face and scalp. Instead of wide and deep excisions with standardized margins, "personalized excisions" are required for primary cutaneous melanoma. The concept of clinical safety margins is a relic of former times that has no place in modern medicine.

Entities:  

Mesh:

Year:  2019        PMID: 31490196     DOI: 10.1097/DAD.0000000000001450

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

1.  A Ferroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Cutaneous Melanoma.

Authors:  Congcong Xu; Hao Chen
Journal:  Front Genet       Date:  2021-08-10       Impact factor: 4.599

2.  Characteristics, treatment and outcomes of 589 melanoma patients documented by 27 general practitioners on the Skin Cancer Audit Research Database.

Authors:  Jeremy Hay; Jeff Keir; Clara Jimenez Balcells; Nikita Rosendahl; Martelle Coetzer-Botha; Tobias Wilson; Simon Clark; Astrid Baade; Cath Becker; Luke Bookallil; Chris Clifopoulos; Tony Dicker; Martin Paul Denby; Douglas Duthie; Charles Elliott; Paul Fishburn; Mark Foley; Mark Franck; Irene Giam; Patricio Gordillo; Alister Lilleyman; Roger Macauley; James Maher; Ewen McPhee; Michael Reid; Bob Shirlaw; Graeme Siggs; Robert Spark; John Stretch; Keith van Den Heever; Thinus van Rensburg; Chris Watson; Harald Kittler; Cliff Rosendahl
Journal:  Australas J Dermatol       Date:  2022-04-19       Impact factor: 2.481

3.  Dermoscopic Predictors of Tumor Thickness in Cutaneous Melanoma: A Retrospective Analysis of 245 Melanomas.

Authors:  Enrique Rodríguez-Lomba; Belén Lozano-Masdemont; Lula María Nieto-Benito; Elisa Hernández de la Torre; Ricardo Suárez-Fernández; José Antonio Avilés-Izquierdo
Journal:  Dermatol Pract Concept       Date:  2021-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.